FilingSEC EDGAR424B3
Paxalisib Preclinical Data and Clinical Trial Expansion
· SEC accepted
StageClinical
Filing content
The company reported positive preclinical data for Paxalisib in immunotherapy-resistant colorectal cancer and announced the expansion of its clinical trial to include HR+/HER2- breast cancer.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…